Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Washington Drug Letter > FDA Approves Genentech’s Lucentis for Additional Indication in DME

Washington Drug Letter

Aug. 20, 2012 | Vol. 44 No. 33

FDA Approves Genentech’s Lucentis for Additional Indication in DME

The FDA has approved Genentech’s Lucentis for an additional indication in diabetic macular edema (DME), making it the first and only agency-approved treatment for the condition.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

Full Issue Correction Astellas Scraps EU Marketing Plans for Kidney Cancer Candidate Merck Ends Trials For Once-Promising Parkinson’s Drug

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.